Interleukin-7 gene therapy

Drug Profile

Interleukin-7 gene therapy

Latest Information Update: 28 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Boehringer Ingelheim; Freie Universitat Berlin; Henry M. Jackson Foundation for the Advancement of Military Medicine; Walter Reed Army Institute of Research
  • Developer Amgen; Freie Universitat Berlin; Henry M. Jackson Foundation for the Advancement of Military Medicine; Nonindustrial source; Walter Reed Army Institute of Research
  • Class Antivirals; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action B cell stimulants; Interleukin 7 stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; HIV infections

Most Recent Events

  • 28 Nov 2006 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 28 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 28 Nov 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top